|
|
|
|
Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published
ExThera Medical announced today that the results of a preliminary study (Cytokines in blood from septic patients interact with surface immobilized heparin) of its proprietary medical device, Seraph extracorporeal affinity therapy, have been published in...
|
|
|
PolyMedix Announces Planned Milestones for 2010
Companies mentioned in this article: PolyMedix, Inc.RADNOR, Pa. -- (BUSINESS WIRE) -- PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute...
|
|
|
PolyMedix Announces Planned Milestones for 2010
PolyMedix, Inc.(OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, provided an overview of its 2010 clinical milestones in a...
|
|
|
Export amount of Heparin in Nov. 2009
_ Export amount of Heparin in Nov.2009.
|
|
|
Study at the Karolinska Institute suggests potential for reducing the high death rate from sepsis, one of the
BERKELEY, Calif.--(EON: Enhanced Online News)--ExThera Medical announced today that the results of a preliminary study (Cytokines in blood from septic patients interact with surface immobilized heparin) of its proprietary medical device, Seraph...
|
|
|
Bridging anticoagulation discrepancies detected among US hospitals
MedWire News: Anticoagulation management in patients undergoing surgery varies among hospitals and does not depend solely on patient characteristics, suggest study findings published in the American Journal of Medicine.The researchers examined the rates of...
|
|
|
Study at the Karolinska Institute suggests potential for reducing the high death rate from sepsis, one of the top-10 causes of death in the U.S.
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); BERKELEY, Calif.- (Business Wire) ExThera Medical announced today that the results of a preliminary study (Cytokines in blood from septic patients interact with surface immobilized heparin)...
|
|
|
Study at the Karolinska Institute suggests potential for reducing the high death rate from sepsis, one of the
Study results published in current issue of ASAIO Journal BERKELEY, Calif.--(BUSINESS WIRE)--ExThera Medical announced today that the results of a preliminary study (Cytokines in blood from septic patients interact with surface immobilized heparin) of its...
|
|
|
Study at the Karolinska Institute suggests potential for reducing the high death rate from sepsis, one of the top-10 causes of death in the U.S.
Study results published in current issue of ASAIO Journal BERKELEY, Calif.--(BUSINESS WIRE)-- ExThera Medical announced today that the results of a preliminary study ("Cytokines in blood from septic patients interact with surface immobilized heparin") of...
|
|
|
Study at the Karolinska Institute suggests potential for reducing the high death rate from sepsis, one of the top-10 causes of death in the U.S.
Study results published in current issue of ASAIO Journal BERKELEY, Calif.--(BUSINESS WIRE)--ExThera Medical announced today that the results of a preliminary study (Cytokines in blood from septic patients interact with surface immobilized heparin) of its...
|
|
|
Study at the Karolinska Institute suggests potential for reducing the high death rate from sepsis, one of the top-10 causes of death in the U.S.
Companies mentioned in this article: ExThera Medical BERKELEY, Calif.-- (BUSINESS WIRE) -- ExThera Medical announced today that the results of a preliminary study (Cytokines in blood from septic patients interact with surface immobilized heparin) of...
|
|
|
Study at the Karolinska Institute suggests potential for reducing the high death rate from sepsis, one of the top-10 causes of death in the U.S.
Companies mentioned in this article: ExThera Medical BERKELEY, Calif.-- (BUSINESS WIRE) -- ExThera Medical announced today that the results of a preliminary study (Cytokines in blood from septic patients interact with surface immobilized heparin) of...
|
|
|
Study at the Karolinska Institute suggests potential for reducing the high death rate from sepsis, one of the top-10 causes of death in the U.S.
ExThera Medical announced today that the results of a preliminary study ("Cytokines in blood from septic patients interact with surface immobilized heparin") of its proprietary medical device, Seraph extracorporeal affinity therapy, have been published in...
|
|
|
Study at the Karolinska Institute suggests potential for reducing the high death rate from sepsis, one of the top-10 cau
BERKELEY, Calif.- (BUSINESS WIRE) - ExThera Medical announced today that the results of a preliminary study ("Cytokines in blood from septic patients interact with surface immobilized heparin" ) of its proprietary medical device, Seraph extracorporeal...
|
|
|
Study at the Karolinska Institute suggests potential for reducing the high death rate from sepsis, one of the top-10 causes of death in the U.S.
BERKELEY, Calif.--(BUSINESS WIRE)--ExThera Medical announced today that the results of a preliminary study (Cytokines in blood from septic patients interact with surface immobilized heparin) of its proprietary medical device, Seraph extracorporeal...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a...
|
|
|
Calcinosis Cutis: A Rare Reaction to Subcutaneous Injections of Calcium-Containing Heparin in Patients With Renal Failure
Boccara O et al.Calcinosis of the cutis and the subcutis after subcutaneous injections of calciumcontaining heparin is rare. Calcinosis Cutis: A Rare Reaction to Subcutaneous Injections of Calcium-Containing Heparin in Patients With Renal...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a...
|
|
|
Out of Bounds
My lab story comes from a memory at my first job working as a medical laboratory technician on second shift of a small hospital laboratory.I worked solo--no other techs or phlebotomists with me after a certain hour. I had many busy nights and many stories...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a...
|
|
|
FDA Finds Drug Official Had No Conflict, Stepped Aside Voluntarily
WASHINGTONThe collaboration between the Food and Drug Administration's top drug official and scientists for a pharmaceutical company on research during the 2008 heparin crisis a time when the firm had a drug application pending -- did not constitute a...
|
